BRAF and melanoma: In BRAF V600E melanoma cell lines (A375), a wide genome-scale activation screening using the Clustered Regularly Interspaced Short Palindromic Repeats Cas9 (CRISPR-Cas9) technique has identified an lncRNA—named EQTN MOB3B IFNK C9orf72 enhancer RNA I (EMICERI)—as a prediction factor of resistance to targeted therapy.